Masters | Postgraduate Course - Biopharmaceutical Development MSc Course Details within University of Leeds
Faculty of Biological Sciences
Tel:0113 343 8186
UK/EU: £20,000 (total). International: £30,000 (total)
Biopharmaceutical Development MSc
MSc: 20 months full-time
The programme is designed to train talented scientists wishing to pursue a career in drug development within the biopharmaceutical industry globally. On completion of this course you will be able to apply what you have learned to various roles in biologics medicine development in a biotechnology, contract manufacturing, contract research organisation or pharmaceutical company and enhance the value you can add to that organisation with immediate effect.
The unique programme is 20 months in duration. The first six months will be taught components covering the pathway from biological drug discovery to the commercialisation of such medicines. This part of the course is delivered within the University of Leeds with tutors from the university and from industry. It is followed by a salaried, one year placement in a biopharmaceutical company where you will focus on at least one aspect of drug discovery/development and conduct a research project.
Biopharmaceutical Drug Discovery
Normally a 2:1 honours degree or equivalent in a Biological Sciences subject, Bioprocessing or Biochemical Engineering, but relevant experience may be taken into account. In addition, applicants will need to demonstrate leadership potential, which might be evidenced from academic, sporting, volunteering or other professional experience
IELTS 6.5 overall, with no less than 6.0 in any component.
We use a variety of assessment methods: essays, reports and oral presentations, practical work, data handling and problem solving exercises, group and individual work, many of which are configured to align with professional outputs in this industry (client reports, submission to regulators, investment panels, etc.)
The UK has one of the strongest and most productive life sciences industries in the world, generating turnover of over £56 billion per annum. The pharmaceuticals sector alone accounts for more UK-based business R&D than any other manufacturing sector, accounting for over 22 per cent of all business R&D.
This programme has been developed in direct response to the requirements of the biopharmaceutical industry. The rapid growth of biologics means that there is currently a shortage of highly-trained scientists who understand the basics of the biological drug development pathway and who can apply their scientific training in a regulatory environment.